Related Experiment Video

Updated: Aug 11, 2026

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

Targeting the process of farynesylation for therapy of hematologic malignancies

Judith E Karp1, Jeffrey E Lancet

  • 1The Sidney Kimmel Cancer Center at Johns Hopkins, 1650 Orleans St., Bunting-Blaustein Cancer Research Bldg., Room 289, Baltimore, Maryland 21231-1000, USA. jkarp2@jhmi.edu

Current Molecular Medicine
|November 25, 2005
PubMed

Insights

Farnesyltransferase inhibitors (FTIs) show promise in treating various cancers by blocking signal transduction pathways. Further research is crucial to optimize their use in hematologic disorders like AML.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Farnesyltransferase inhibitors (FTIs) are a class of drugs targeting signal transduction pathways.
  • These inhibitors have demonstrated potential clinical efficacy across a range of malignancies.

Purpose of the Study:

  • To explore the mechanisms of transformed cell response to FTIs.
  • To determine optimal clinical settings for FTI application.
  • To define the role of FTIs in hematologic malignancies, including acute myeloid leukemia (AML).

Main Methods:

  • Clinical trials evaluating FTI efficacy and safety.
  • Correlative laboratory studies investigating FTI effects on cellular metabolism.
  • Analysis of FTI modulation of signaling pathways in normal and malignant marrow precursors.

Main Results:

  • FTIs exhibit promising clinical activity against a broad spectrum of malignancies.
  • Ongoing and planned clinical trials will establish optimal FTI roles.
  • Laboratory studies are elucidating FTI-mediated alterations in cellular metabolism and signaling.

Conclusions:

  • FTIs are signal transduction inhibitors with significant therapeutic potential in oncology.
  • Understanding FTI mechanisms is key to optimizing their clinical application.
  • Findings from FTI research will inform the broader use of signal transduction inhibitors.

More Related Videos

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells06:53

Rapid Antibody Glycoengineering in Chinese Hamster Ovary Cells

Published on: June 2, 2022

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...